Analysts have raised AbbVie's stock price target to $237.48 per share due to extended product exclusivity and evolving views on the company's portfolio. Wall Street shows a mix of bullish optimism and caution, emphasizing growth drivers and strategic wins while highlighting concerns like macroeconomic headwinds.